Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin in CD30 Low Mature T-Cell Lymphoma
NCT02588651Phase 2Completed
- Start
- Jun 2016
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in mature T-cell lymphoma (PTCL). Started Jun 2016; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
mature T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT02588651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02588651.